Fig. 2From: The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022Is anti-PD-1 monotherapy still acceptable as a comparator arm in clinical trials? Yes or No. Audience response before and after debateBack to article page